Cetera Advisor Networks LLC Has $62.62 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Cetera Advisor Networks LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 2.7% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 378,322 shares of the company’s stock after buying an additional 10,095 shares during the quarter. Cetera Advisor Networks LLC’s holdings in Johnson & Johnson were worth $62,620,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC increased its stake in shares of Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Norges Bank acquired a new position in Johnson & Johnson in the 4th quarter valued at $4,609,399,000. Providence Capital Advisors LLC grew its stake in Johnson & Johnson by 141,974.0% in the 1st quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock valued at $30,651,000 after buying an additional 4,747,612 shares during the last quarter. Morgan Stanley grew its stake in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Finally, Barclays PLC grew its stake in Johnson & Johnson by 61.0% in the 2nd quarter. Barclays PLC now owns 11,287,765 shares of the company’s stock valued at $1,868,351,000 after buying an additional 4,278,512 shares during the last quarter. Institutional investors and hedge funds own 68.40% of the company’s stock.

Johnson & Johnson Trading Up 0.9 %

Shares of JNJ stock opened at $149.91 on Tuesday. Johnson & Johnson has a 12-month low of $144.95 and a 12-month high of $181.04. The company has a market capitalization of $360.88 billion, a P/E ratio of 11.13, a P/E/G ratio of 3.00 and a beta of 0.58. The firm has a 50-day moving average price of $154.52 and a 200 day moving average price of $160.29. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.14. The firm had revenue of $21.35 billion during the quarter, compared to analysts’ expectations of $21 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. Research analysts forecast that Johnson & Johnson will post 10.1 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 5th. Shareholders of record on Tuesday, November 21st will be given a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 3.18%. The ex-dividend date is Monday, November 20th. Johnson & Johnson’s payout ratio is presently 35.34%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on JNJ shares. Raymond James reduced their price target on shares of Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating for the company in a report on Wednesday, October 18th. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $174.00 to $171.00 and set an “equal weight” rating for the company in a report on Wednesday, October 18th. Atlantic Securities increased their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Wells Fargo & Company reduced their price target on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a report on Thursday, August 31st. Finally, TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $169.19.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.